Celltrion
068270.KS
#881
Rank
ยฃ20.96 B
Marketcap
ยฃ91.41
Share price
3.14%
Change (1 day)
-4.52%
Change (1 year)
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.

P/E ratio for Celltrion (068270.KS)

P/E ratio as of July 2026 (TTM): 48.1

According to Celltrion 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 48.1118. At the end of 2025 the company had a P/E ratio of 40.7.

P/E ratio history for Celltrion from 2008 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202540.7-61.14%
202410562.67%
202364.443.97%
202244.7-9.69%
202149.5-49.48%
202098.117.79%
201983.2-27.7%
201811545.28%
201779.3-7.14%
201685.426.52%
201567.577.15%
201438.1-3.29%
201339.4152.7%
201215.6-40.11%
201126.0-26.42%
201035.431.03%
200927.0-60.87%
200869.0785.83%
20077.79

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.